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Abstract
Background—We analyzed birth outcomes among infants of treatment-naïve, HIV-infected
women from a series of mother-to-child transmission of HIV studies in Blantyre, Malawi.
Methods—Data from six prospective studies at one research site were analyzed. Mean birth
weight (BW) and gestational age (GA), and frequency of low birth weight (LBW; <2500 g) and
preterm (PT) birth (GA<37 weeks) were estimated. We assessed risk factors for LBW and PT
birth using mixed-effects logistic regression. Adjusted odds ratios (AOR) and 95% confidence
intervals (CI) from earlier studies (1989-94) and later studies (2000-07) are presented separately.
Results—The analysis included 8874 HIV-exposed infants. Mean BW and GA ranged from
2793 to 3079 g, and 37.8 to 39.0 weeks. Greater maternal age was consistently (during both the
early and late periods) associated with lower odds of LBW and PT birth; AOR (95% CI) for both
outcomes in the early and late periods, respectively, were 0.98 (0.96-1.00) and 0.97 (0.95-0.99).
Female infant gender was consistently associated with higher odds of PT birth during both periods
and with higher odds of LBW during the later period. During the early period, higher maternal
education was associated with lower odds of LBW (AOR 0.67 (0.48-0.95)) and PT birth (AOR
0.70 (0.51-0.95)) and later birth year was associated with lower odds of PT birth (AOR 0.35
(0.19-0.70)).
Conclusions—BW and GA remained stable within each time period. This analysis provides
important baseline information for monitoring HIV treatment effects on birth outcomes.
Modifiable factors affecting BW and GA should continue to be explored.
Keywords
antiretroviral therapy; pregnancy outcomes; HIV; Malawi; trends
The use of antiretroviral (ARV) drugs for HIV-1 treatment and prevention of mother-to-
child transmission (MTCT) of HIV in low- and middle-income countries has expanded
dramatically since 2003.1 Some African countries with high HIV prevalence and suboptimal
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coverage of prevention of MTCT programs are now considering universal ARV treatment
(ART) for HIV-infected pregnant women.2
Globally, there are conflicting findings on the impact of combination ART on low birth
weight (LBW) and preterm (PT) birth. Studies in Europe and the United States showed a
relatively high rate of PT births among infants of HIV-infected mothers on highly active
antiretroviral therapy (HAART)3-5 and some indication of very LBW among babies born to
protease inhibitor users.6 Others studies from Europe, the Caribbean, Latin America and the
United States, reported no association with birth weight (BW), gestational age (GA), or risk
of stillbirths,78 or an increased risk of PT and LBW birth without ART.9 More broadly, the
extent to which HIV contributes to adverse birth outcomes compared to established non-
HIV-related risk factors, such as demographic, environmental and behavioral factors10 has
been speculated but not well defined.11 A study from Rwanda, prior to ART, looking at
intrauterine growth indicated that maternal HIV was significantly associated with LBW but
not with PT birth12 while another report from the same study suggested infant HIV status is
a more valuable predictor of BW.13
Existing information on maternal ART and adverse birth outcomes has been derived from
observational studies conducted mainly in developed countries. In most African countries,
information on BW is generated from small studies or national estimates which are not
stratified by maternal HIV status. Similarly, there are no national data on GA. One published
study in Botswana showed lower BW in HIV-uninfected infants exposed to HAART in-
utero compared to those exposed to zidovudine alone; these lower birth weights were
corrected in the first 6 months of life.14 The same trial concluded protease inhibitors were
associated with increased PT delivery but not with excess hospitalization or mortality.15
Trend data on mean BW and GA among infants of ART-naïve, HIV-infected women could
be instrumental in providing baseline estimates when monitoring birth outcomes associated
with ART exposure. These data could also assist in establishing local and regional
surveillance databases to study the effects of ART on these outcomes, as coverage and
access continue to expand. In Malawi, several MTCT observational and interventional
studies were conducted at a single site in Blantyre over the past 20 years.16 This provides a
unique opportunity to document BW and GA over time in cohorts of HIV-infected women
and their HIV-exposed children. These studies predated use of ART during pregnancy for
prevention of MTCT of HIV in Malawi. In this paper, we examine trends in mean BW and
GA, and the proportion of LBW and PT births in cohorts of infants born to HIV-infected,
ART-naïve women screened and enrolled in multiple MTCT studies in Blantyre, Malawi.
We also assess risk factors associated with these pregnancy outcomes.
MATERIALS AND METHODS
Setting and design of the studies
Blantyre District, including Blantyre City, has approximately one million inhabitants in the
Southern Region of Malawi. HIV prevalence among women of reproductive age in the
District’s health care settings is approximately 21%17. UNAIDS estimates that nationally, in
2009, 11% of individuals aged 15-49 years were living with HIV.1 The Johns Hopkins
University Research Project in collaboration with Malawian investigators has conducted
MTCT of HIV research in Blantyre from 1989 to the present.
Data from six HIV MTCT studies were included in this analysis: the International
Collaboration of AIDS Research (ICAR, 1989-93), Preparation of AIDS Vaccine Evaluation
(PAVE, 1992-94), Perinatal Infection Project (PIP, 1994-95), Nevirapine/Zidovudine (NVP/
ZDV) trial (NVAZ, 2000-04), HIV Prevention Trials Network (HPTN, 2001-03), and Post-
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Exposure Prophylaxis of Infants (PEPI, 2004-07). All studies included prospective cohorts
of HIV-infected women enrolled during pregnancy or at delivery, and followed with their
children postnatally at regular intervals. All women were recruited from the antenatal clinics
at the main hospital in Blantyre (Queen Elizabeth Central Hospital) and from five health
centers throughout the City representing the hospital’s catchment area. ICAR18 and PAVE18
were observational cohort studies to determine rates and risk factors for HIV MTCT. PIP19,
NVAZ2021, HPTN22 and PEPI2324 were phase 3 clinical trials to decrease the rate of HIV
MTCT using ARV and non-ARV interventions. In NVAZ, HPTN and PEPI, women
received single-dose oral NVP (200 mg) at the time of delivery and their infants received
single-dose oral NVP immediately after birth (2 mg/kg). No participant received ART
during pregnancy. No infants were enrolled from 1996 to 1999. Therefore, two distinct
periods are considered: 1989-94 (IACR, PAVE and PIP studies) and 2000-07 (NVAZ,
HPTN and PEPI studies). All studies were approved by appropriate institutional reviews
boards in the United States (Johns Hopkins Bloomberg School of Public Health) and in
Malawi (Ministry of Health and College of Medicine in Malawi).
Study procedures
Women were counseled, consented and tested for HIV using conventional HIV antibody
tests at the time of each study (either ELISA with Western blot or rapid tests). HIV-infected
women were enrolled after learning about study procedures and providing written informed
consent. There were important exclusions of relevance to this analysis. In the NVAZ
protocol (2000-04), infants who were PT or admitted to the neonatal care unit immediately
following delivery were excluded (unless the clinician determined it was safe for the infant
to receive oral ARV prophylaxis). In the HPTN and PEPI protocols (2001-2007) infants
with severe clinical conditions were excluded, some of whom may have been born with low
BW and/or low GA. The data from these three studies were grouped in the analysis for their
similar study designs and populations. The results are presented with and without
observations from the NVAZ study cohort, given its explicit exclusion of PT infants per the
approved protocol. Demographic, medical, obstetric and behavioral information was
collected on structured case report forms. Physical examinations of the mother and infant
were conducted at birth and subsequent visits. BW and GA measurements were performed
by trained research nurses as soon as possible following delivery, and always within 24
hours of an infant’s birth. GA was typically assessed using the Ballard score25; when this
information was not available, GA was estimated based on date of last menstrual period and
date of delivery. Ultrasounds were not used to confirm GA.
Data analyses
Data from the six studies were analyzed to determine mean BW in grams (g), mean GA in
weeks and standard errors (SE) for each study and across all studies. The frequency of LBW
(BW<2500 g), PT birth (GA<37 weeks) and LBW among full-term infants (BW<2500 g and
GA ≥37 weeks) was also estimated. Mean BW and GA were plotted by birth year separately
for the two periods, 1989-94 and 2000-07, to acknowledge differences in design and
exclusion criteria. Including or excluding infants from multiple births did not impact the
results and no exclusion for multiple births was applied.
Multiple logistic and linear regression models were used to assess the association of socio-
demographic factors with LBW and PT birth separately for the two study periods. Selection
of variables for inclusion in the models was based on epidemiological and biological
considerations as well as availability of the same variables across all studies. We used
generalized linear mixed models for dichotomous and continuous outcomes (a multilevel
approach) to account for variation at the individual-level and potential clustering of
outcomes at the study cohort level. Factors associated with BW and GA in the linear and
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logistic regression models were similar; therefore, we present only the results of the mixed
effects logistic regression models. Birth year, which was the same as year of enrollment and
highly correlated with study cohort, was included as a covariate in the logistic regression
models to account for potential differences by calendar time. Infants with missing BW were
excluded from the analysis. Body mass index, socio-economic status and mode of delivery
were included in the univariable but not in the multivariable analyses because these
variables were not collected in PIP (body mass index, socioeconomic status) and PAVE
(mode of delivery) studies. We defined high socioeconomic status as living in a household
with both electricity and piped water. P values <0.05 were considered statistically
significant. SAS version 9.2 (SAS Institute, Carey, North Carolina) was used for all
statistical analyses.
RESULTS
Six MTCT studies conducted in Blantyre, Malawi contributed data from 8753 HIV-infected
mothers (range: 235-3352 per study) and 8874 HIV-exposed infants to this analysis (3042
infants from the ICAR, PAVE and PIP studies; 5832 infants from the NVAZ, HPTN and
PEPI studies). Table 1 describes key socio-demographic and clinical characteristics of the
mothers and children. Differences across studies were small but statistically significant, with
the exception of infant gender, which was distributed similarly in all studies. Notably, the
rate of cesarean sections (elective and non-elective combined) in the PIP study (12.3%) was
substantially higher than in other studies (1.0-5.3%).
The mean BW and GA of HIV-exposed infants across the six cohorts was 2953 g (SE ±5.3)
and 38.5 weeks (SE±0.03), respectively (Table 2). The differences in mean BW and GA
across studies was <300 g for BW and 1.2 weeks for GA. Table 2 also shows the overall
proportions of LBW, PT and LBW among full-term infants which were 12.9%, 7.6% and
5.2%, respectively. During the earlier period (1989-94; ICAR, PAVE and PIP studies),
proportions for LBW (range 19.9-21.5%), PT (13.9-14.9%) and LBW (5.9-7.0%) for full
term infants were similar across time (p>0.05); during the later period (2000-07; NVAZ,
HPTN and PEPI), proportions for the three outcomes (ranges 5.1-17.8%; 1.3-12.9%; and
3.7-5.4%, respectively) were variable across time (p<0.01).
Figure 1 show trends in mean BW by birth year. Although the number of infants born each
year was variable (range: 93-2142 infants), the mean BW for each year was not substantially
different within each of the two study periods. From 1989-94, mean BW ranged from 2772 g
(SE ±26.7) to 2936 g (SE ±42.3); and from 2925 g (SE ±43.6) to 3092 g (SE ±15.2) in
2000-07 (Figure 1). The variability in GA during the two study periods was also relatively
minimal ranging from 37.8 (SE ±0.1) to 39.2 (SE ±0.2) weeks (Figure 2, supplemental
digital conent).
Table 3 shows the adjusted odds ratios (AOR) and 95% confidence intervals (CI) from
mixed effects logistic regression for the LBW and PT birth outcomes in the early period
(1989-94) and Table 4 shows results for the later period (2000-07). In the early period,
maternal education was protective against LBW (AOR 0.67, CI: 0.48-0.95) and PT birth
(AOR 0.70, 0.51-0.95). Maternal age was also protective against LBW (AOR 0.98, CI:
0.96-1.00) and PT birth (AOR 0.98, CI: 0.96-1.00). Birth year was associated with lower PT
risk (AOR 0.35, CI: 0.19-0.70). Female gender was associated with a higher risk of PT
compared to male gender (AOR 1.24, CI: 1.04-1.48). In the later period (Table 4), maternal
age protected against LBW (AOR 0.97, CI: 0.95-0.99) and PT birth (AOR 0.98, CI:
0.96-1.00), while female infant gender was associated with higher odds for LBW (AOR
1.48, CI: 1.22-1.79) and PT birth (AOR 1.23, CI: 1.05-1.44). Sensitivity analyses excluding
observations from NVAZ revealed virtually no differences for the LBW outcome, as shown
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in Table 4. There was some attenuation in the effect of maternal age and infant gender on PT
birth without NVAZ data, although the direction of the effect remained the same for both
covariates.
DISCUSSION
Data from six prospective studies conducted in Blantyre, Malawi were analyzed to assess
trends in mean BW and GA, and frequency of LBW and PT birth during two periods which
approximately represent non-ARV (1989-94) and ARV (2000-07) eras of prevention of HIV
MTCT. Mothers of these HIV-exposed infants did not receive ARV drugs or HAART for
their own health during pregnancy.
Our findings show that mean BW and GA remained relatively stable with no notable
differences within each time period. The frequency of LBW (range 19.9-21.5%) and PT
(range 13.9-14.9%) also did not vary substantially during the earlier period (1989-94) when
study exclusion criteria for infants were minimal. The proportion of LBW infants in these
studies was higher than national estimate of 16% for Malawi in 2000, and World Health
Organization estimates for the Southern Africa Region in 2000 of 14.6%, possibly because
all mothers in these studies were HIV-infected.26 Estimates for the proportion of PT births
were lower than the overall estimate for the Southern Africa Region of 17.5% but similar to
other estimates from Africa (range 8.7-14.3%).27 The studies in the later period (2000-07)
were all major clinical trials and required exclusion of newborns with severe illness, which
is closely associated with LBW and PT birth, for safety reasons. Therefore, the proportions
of LBW or PT infants were variable during this later period, and most likely underestimate
true incidence of these outcomes. Because of the substantial number of observations
(n=2020, 23%) contributed by the NVAZ study to the overall analysis, we opted to include
this study and present the results with and without the NVAZ data. The frequency of LBW
among full term infants showed limited variability over time (3.7-7.0%).
BW is a major predictor of infant morbidity and mortality. The duration of gestation and
fetal growth in-utero are important determinants of BW and are influenced by maternal,
infant and environmental factors. Maternal HIV infection is an additional factor associated
with LBW and PT birth.28-32 This could result from complications to the mother herself,
intrauterine infection of the fetus, or both. In this analysis, several factors were
independently associated with LBW and PT birth. An increase in maternal age was
consistently protective; e.g., an increase in age of 1 year was associated with a 2-3%
decrease in odds of LBW or PT birth in all models, irrespective of the time of the study.
Increase in maternal education was also protective against both LWB and PT birth during
the earlier period (1989-94). Maternal education, as a socio-economic indicator, may
influence maternal nutrition or access to care. Consistent with other studies,26 female infant
gender in Blantyre, Malawi was associated with higher odds of being LBW or PT. The risk
factors examined in this analysis were not comprehensive and although other relevant
covariates were available from individual studies, such as maternal syphilis status,
comparability of data across studies precluded inclusion of additional variables.
Consistent with our observation in the univariable analysis that mean BW and frequency of
LBW and PT were stable during the two study periods, birth year was not significantly
(p>0.1) associated with either LBW or PT birth after adjusting for other factors. The
exception was for PT birth in the early period (1989-94); an increase of one year was
associated with significantly lower risk of PT birth in the multivariable analysis. Birth year
may be a proxy for a factor we did not include in the analysis.
This analysis of 8874 HIV-exposed infants provides important baseline information for
monitoring impact of ARV use during pregnancy and its potential effects on pregnancy
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outcomes among women who deliver in the health facilities. In Malawi, an ambitious
program of life-long HAART for all HIV-infected pregnant women regardless of CD4 cell
count has been introduced to prevent HIV MTCT for current and future pregnancies and to
improve maternal health.233 Monitoring of this wider use of ARVs should include both
safety and effectiveness. A major strength of this analysis is the availability of data from a
single research site to assess trends across several years that encompassed the earlier and
later periods of the HIV epidemic in Malawi. All studies had prospective designs and
followed comparable protocols for recruitment and study procedures. Exclusion of sick
infants in the later studies limits generalizability of these findings, which should not be taken
to represent all infants born in Malawi during the study period. Nonetheless, the differences
in mean BW compared with earlier years were not substantial. We were not able to include
births from 1995 to 1999 in this analysis. Expectations are high that ART will substantially
improve health outcomes in sub-Saharan Africa as has been achieved in developed
countries.3435 Treatment for mothers should be equally accompanied by ongoing support for
the infant from the time of birth. BW and GA are established indicators to monitor progress
and reverse high levels of morbidity and mortality.
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Figure 1. Mean birth weight of infants born to treatment-naïve HIV-infected mothers, 1989–
1994 and 2000–2007
charts the mean birth weight and 95% confidence intervals (CI) among infants enrolled in
six prospective studies in Blantyre, Malawi by year of birth, with sample sizes, point
estimates and standard errors (SE) provided below the graph. Figure 2, available in the
supplemental digital content, charts a similar distribution for mean weeks of gestation by
birth year in the two study periods.
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